GlassScriptPhysician profile
Chad Koyanagi
NPI 1770536088
$11,240.50
in general payments reported to CMS, 2019-2025
12 companies · $1,515 in 2025
The $1,515 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $54.59 · 2021: $4,209 · 2022: $1,128 · 2023: $1,436 · 2024: $2,235 · 2025: $1,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,181 · Education: $4.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,180.64 |
| Education | $4.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $4,689.57 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,969.21 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Janssen Scientific Affairs, LLC | $897.57 | 2019-2025 | Invega Sustenna, Spravato |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $722.75 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rejoyn |
| Abbvie INC. | $690.26 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $644.25 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Indivior INC. | $468.93 | 2021-2024 | Perseris, Sublocade |
| Neurocrine Biosciences, INC. | $306.50 | 2021-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $245.44 | 2024-2025 | Cobenfy |
| Allergan, INC. | $243.00 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $238.02 | 2024-2025 | Caplyta |
| Gilead Sciences, INC. | $125.00 | 2025 | Yeztugo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Koyanagi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.